ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2040

Effective Management of Idiopathic Recurrent Pericarditis with Anakinra in Clinical Practice

Martin Michaud1, Laurent Sailler2, Mélanie LEMEU3, Brice CASTEL4, Fabienne Vacheret5, Laurent Prudhomme6 and Grégory Pugnet7, 1Clinique Saint Exupery, Toulouse, France, 2CHU Toulouse, Toulouse, France, 3CH Albi, Albi, France, 4CH TARBES, Tarbes, France, 5CH Perpignan, Perpignan, France, 6CH Castres, Castres, France, 7Toulouse Rangueil University Hospital, Toulouse, France

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Biologicals, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory syndrome marked by recurrent pericardial inflammation after an initial episode of acute pericarditis. Standard treatment involves colchicine and aspirin/NSAIDs, with corticosteroids as second-line therapy and immunosuppressive drugs, including targeted therapies like anakinra, as third-line options. Anakinra, an interleukin-1 inhibitor, has shown promise in treating IRP. This study aimed to evaluate the safety and efficacy of anakinra in real-life settings.

Methods: Patients with IRP who received anakinra from 2018 to 2024 in Midi-Pyrénées, France, were retrospectively identified. They met the 2015 ESC criteria for recurrent pericarditis. Demographic data, clinical features, and treatment responses were analyzed. A complete response was defined as the absence of symptoms, elevated C-reactive protein, and pericardial effusion. Event-free survival (EFS) was estimated using the Kaplan-Meier method. The glucocorticoid-sparing effect was evaluated with Fisher’s exact test, with significance set at 0.05.

Results: The study enrolled 12 patients, with 4 (33%) males and 8 females. The mean age at diagnosis was 42.6 ± 13.6 years. All patients presented with chest pain, elevated C-reactive protein levels, and pericardial effusion. Characteristic ECG changes were noted in 7 patients (58%). Additionally, 7 patients (58%) had associated pleural effusion, and 4 (33%) experienced cardiac tamponade. Initial treatment consisted of colchicine combined with aspirin or NSAIDs as first-line therapy, followed by corticosteroids as second-line therapy. Surgical pericardial drainage was performed in 6 patients (50%).

Among the participants, 10 (83%) were corticosteroid-dependent, and 2(16.6%) were corticosteroid-resistant. Patients had an average of 5.5 ± 1.4 pericarditis attacks before starting anakinra, with a mean duration from the first attack to anakinra initiation of 15.4 ± 13.9 months.

Anakinra was administered daily via subcutaneous injection (100 mg/day) to all patients. Ten patients (83.3%) received concomitant colchicine with anakinra. The mean duration of anakinra treatment was 28.4 ± 21.3 months. During anakinra therapy, daily corticosteroid use significantly decreased from 17.9 ± 10.68 mg to 0 mg (p < 0.005). A complete response was observed in all patients (100%).

An attempt to discontinue anakinra was made in 10 patients (83.3%): 3 patients experienced pericarditis relapse, and 3 successfully discontinued anakinra treatment. All relapses were managed by reintroducing daily 100 mg anakinra injections. The event-free survival rate at 18 months of anakinra use was 75%. No serious adverse events were reported during follow-up.

Conclusion: Anakinra is a safe and effective treatment for patients with idiopathic recurrent pericarditis resistant to conventional therapies. It significantly reduced the frequency of pericarditis attacks and enabled the discontinuation of corticosteroids in most patients. These findings support anakinra as a valuable third-line therapy for managing IRP.

Supporting image 1

PATIENTS CHARACTERISTICS

Supporting image 2

ANAKINRA TREATMENT IN PATIENTS WITH IDIOPATHIC RECURRENT PERICARDITIS

Supporting image 3

RELAPSE FREE SURVIVAL


Disclosures: M. Michaud: None; L. Sailler: None; M. LEMEU: None; B. CASTEL: None; F. Vacheret: None; L. Prudhomme: None; G. Pugnet: None.

To cite this abstract in AMA style:

Michaud M, Sailler L, LEMEU M, CASTEL B, Vacheret F, Prudhomme L, Pugnet G. Effective Management of Idiopathic Recurrent Pericarditis with Anakinra in Clinical Practice [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/effective-management-of-idiopathic-recurrent-pericarditis-with-anakinra-in-clinical-practice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effective-management-of-idiopathic-recurrent-pericarditis-with-anakinra-in-clinical-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology